Page 174 - 2018_11-Haematologica-web

M. Pollari et al.
phase II trial. Haematologica. 2015;
100(2):238-245.
14. Kiyasu J, Miyoshi H, Hirata A, et al.
Expression of programmed cell death lig- and 1 is associated with poor overall sur- vival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193- 2201.
15. Kwon D, Kim S, Kim PJ, et al. Clinicopathological analysis of pro- grammed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology. 2016; 68(7):1079-1089.
16. Goodman A, Patel SP, Kurzrock R. PD-1- PD-L1 immune-checkpoint blockade in B- cell lymphomas. Nature reviews Clinical oncology. 2017;14(4):203-220.
17. Eyre TA, Collins GP. Immune checkpoint inhibition in lymphoid disease. Br J Haematol. 2015;170(3):291-304.
18. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68- 83.
19. Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lym- phoma. Blood. 2017;130(22):2420-2430.
20. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-562.
21. Lau J, Cheung J, Navarro A, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.
22. Blom S, Paavolainen L, Bychkov D, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017; 7(1):15580.
23. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised Fourth Edition. 2017; Volume 2.
24. Carpenter AE, Jones TR, Lamprecht MR, et al. CellProfiler: image analysis software for identifying and quantifying cell pheno- types. Genome Biol. 2006;7(10):R100.
25. Leivonen S-K, Pollari M, Brück O, et al. Clinical impact of the T/NK-cell signature predicts poor survival in patients with pri- mary testicular and diffuse large B-cell Lymphomas. Blood. 2017;130 (Suppl 1):#4027.
26. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793- 800.
27. Wherry EJ, Kurachi M. Molecular and cellu- lar insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.
28. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
29. Pauken KE, Wherry EJ. Overcoming T cell
exhaustion in infection and cancer. Trends
Immunol. 2015;36(4):265-276.
30. Butte MJ, Keir ME, Phamduy TB, Sharpe
AH, Freeman GJ. Programmed death-1 lig- and 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
31. Park JJ, Omiya R, Matsumura Y, et al. B7- H1/CD80 interaction is required for the induction and maintenance of peripheral T- cell tolerance. Blood. 2010;116(8):1291- 1298.
32. XiaoY,YuS,ZhuB,etal.RGMbisanovel binding partner for PD-L2 and its engage- ment with PD-L2 promotes respiratory tol- erance. J Exp Med. 2014;211(5):943-959.
33. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a patho- logic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 2009; 106(15):6303-6308.
34. Bally AP, Lu P, Tang Y, et al. NF-kappaB reg- ulates PD-1 expression in macrophages. J Immunol. 2015;194(9):4545-4554.
35. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499.
36. Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071-3073.
1914
haematologica | 2018; 103(11)